# Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events

> **NCT02103101** · NA · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 68 (actual)

## Conditions studied

- Anticoagulants
- Thromboembolism
- Hemorrhage

## Interventions

- **OTHER:** Measurement of Plasma Concentrations of NOACs
- **GENETIC:** Identification of ABCB1 polymorphisms coding for P-gp

## Key facts

- **NCT ID:** NCT02103101
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-13
- **Primary completion:** 2017-10-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2018-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103101, "Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02103101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*